文献速递生殖医学母胎医学

高反应患者冻胚策略与激动剂触发联合低剂量hCG黄体支持的随机对照试验

The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial.
PubMed 文献 · Hum Reprod · 2020-01-01

该随机对照试验纳入212例对卵巢刺激高反应(≥18个≥11mm卵泡)的IVF/ICSI患者,比较冻存全部胚胎后冻胚移植与GnRH激动剂触发后新鲜胚胎移植联合低剂量hCG强化黄体支持。两组临床妊娠率和活产率无显著差异,但中重度OHSS仅发生于低剂量hCG组(8.6% vs 0%,P<0.01)。

要点

  • 高反应患者冻胚策略与新鲜移植联合低剂量hCG黄体支持的妊娠结局无显著差异。
  • 中重度OHSS仅见于低剂量hCG强化黄体支持的新鲜移植组(9/105,8.6%)。
  • 不建议将新鲜移植联合低剂量hCG黄体支持作为高反应患者的常规一线治疗。

核心结论

  • 高反应患者中,冻胚策略与激动剂触发后新鲜移植联合低剂量hCG强化黄体支持的妊娠率无显著差异,但后者中重度OHSS发生率更高。

研究设计与样本

  • 随机对照试验,纳入2014至2017年接受IVF/ICSI且对卵巢刺激高反应(≥18个直径≥11mm卵泡)的女性,共212例(每组106例)。

主要发现

  • 意向性分析显示,新鲜移植组与冻胚组首次移植后临床妊娠率分别为51/105(48.6%)和57/104(54.8%),相对风险1.13(95%CI 0.87-1.47,P=0.41)。
  • 活产率分别为41/104(39.4%)和42/101(41.6%),两组无显著差异。
  • 中重度OHSS仅见于低剂量hCG组:9/105(8.6%,95%CI 3.2%-13.9%)vs 0/104(95%CI 0-3.7),P<0.01。

关键数值与推荐

  • 高反应定义:卵巢刺激后≥18个直径≥11mm的卵泡。
  • 低剂量hCG强化黄体支持方案:取卵日1500 IU hCG,联合口服雌二醇2mg每日两次及微粒化黄体酮200mg阴道每日三次。
  • 主要结局:首次胚胎移植后7周临床妊娠率。

临床怎么用

  • 对于高反应患者,冻胚策略可避免中重度OHSS风险,而新鲜移植联合低剂量hCG黄体支持仍可能发生OHSS。
  • 在推荐新鲜移植联合低剂量hCG黄体支持作为常规一线治疗前需慎重考虑。

局限性

  • 样本量基于19%的临床妊娠率绝对差异计算,因此本试验观察到的小差异不能可靠排除为非显著。
  • 研究无外部资助,作者无利益冲突。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does the freeze-all strategy in high-responders increase pregnancy rates and improve safety outcomes when compared with GnRH agonist triggering followed by low-dose hCG intensified luteal support with a fresh embryo transfer? SUMMARY ANSWER: Pregnancy rates after either fresh embryo transfer with intensified luteal phase support using low-dose hCG or the freeze-all strategy did not vary significantly; however, moderate-to-severe ovarian hyperstimulation syndrome (OHSS) occurred more frequently in the women who attempted a fresh embryo transfer. WHAT IS KNOWN ALREADY: Two strategies following GnRH agonist triggering (the freeze-all approach and a fresh embryo transfer attempt using a low-dose of hCG for intensified luteal phase support) are safer alternatives when compared with conventional hCG triggering with similar pregnancy outcomes. However, these two strategies have never been compared head-to-head in an unrestricted predicted hyper-responder population. STUDY DESIGN, SIZE, DURATION: This study included women with an excessive response to ovarian stimulation (≥18 follicles measuring ≥11 mm) undergoing IVF/ICSI in a GnRH antagonist suppressed cycle between 2014 and 2017. Our primary outcome was clinical pregnancy at 7 weeks after the first embryo transfer. Secondary outcomes included live birth and the development of moderate-to-severe OHSS. PARTICIPANTS/MATERIALS, SETTING, METHODS: Following GnRH agonist triggering, women were randomized either to cryopreserve all good-quality embryos followed by a frozen embryo transfer in an subsequent artificial cycle or to perform a fresh embryo transfer with intensified luteal phase support (1500 IU hCG on the day of oocyte retrieval, plus oral estradiol 2 mg two times a day, plus 200 mg of micronized vaginal progesterone three times a day). MAIN RESULTS AND THE ROLE OF CHANCE: A total of 212 patients (106 in each arm) were recruited in the study, with three patients (one in the fresh embryo transfer group and two in the freeze-all group) later withdrawing their consent to participate in the study. One patient in the freeze-all group became pregnant naturally (clinical pregnancy diagnosed 38 days after randomization) prior to the first frozen embryo transfer. The study arms did not vary significantly in terms of the number of oocytes retrieved and embryos produced/transferred. The intention to treat clinical pregnancy and live birth rates (with the latter excluding four cases lost to follow-up: one in the fresh transfer and three in the freeze-all arms, respectively) after the first embryo transfer did not vary significantly among the fresh embryo transfer and freeze-all study arms: 51/105 (48.6%) versus 57/104 (54.8%) and 41/104 (39.4%) versus 42/101 (41.6%), respectively (relative risk for clinical pregnancy 1.13, 95% CI 0.87-1.47; P = 0.41). However, moderate-to-severe OHSS occurred solely in the group that received low-dose hCG (9/105, 8.6%, 95% CI 3.2% to 13.9% vs 0/104, 95% CI 0 to 3.7, P < 0.01). LIMITATIONS, REASONS FOR CAUTION: The sample size calculation was based on a 19% absolute difference in terms of clinical pregnancy rates, therefore smaller differences, as observed in the trial, cannot be reliably excluded as non-significant. WIDER IMPLICATIONS OF THE FINDINGS: This study offers the first comparative analysis of two common strategies applied to women performing IVF/ICSI with a high risk to develop OHSS. While pregnancy rates did not vary significantly, a fresh embryo transfer with intensified luteal phase support may still not avoid the risk of moderate-to-severe OHSS and serious consideration should be made before recommending it as a routine first-line treatment. Future trials may allow us to confirm these findings. STUDY FUNDING/COMPETING INTEREST(S): The authors have no conflicts of interest to disclose. No external funding was obtained for this study. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier NCT02148393. TRIAL REGISTRATION DATE: 28 May 2014. DATE OF FIRST PATIENT’S ENROLMENT: 30 May 2014.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Santos-Ribeiro S, Mackens S, Popovic-Todorovic B, et al. The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial. Hum Reprod. 2020. PMID: 32964939. doi:10.1093/humrep/deaa226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。